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Does ambulatory blood pressure monitoring
aid in the management of patients with
hypertension?
EVIDENCE-BASED ANSWER
Twenty-four hour ambulatory blood pressure moni-
toring (ABPM) has a higher correlation with target
end-organ damage than standard office measure-
ments and is superior for risk stratification. Because
it is more complicated to implement than office-
based measurements, it should be reserved for:
establishing the diagnosis of white-coat hyperten-
sion or borderline hypertension in previously
untreated patients; evaluating previously treated
patients with resistant hypertension; diagnosing and
treating hypertension disorders of pregnancy; and
identifying nocturnal hypertension. (Grade of rec-
ommendation: B, based on consistent cohort studies
and trials, requiring extrapolation in certain clinical
circumstances)
EVIDENCE SUMMARY
The accuracy of ABPM has been validated for use in
the adult, pediatric, and pregnant populations.1
Community-based cohort studies have consistently
shown ABPM to be more reproducible than office
blood pressure measurements.2,3 Also, ABPM corre-
lates better with disease-oriented outcomes, such as
left ventricular mass, retinopathy, and microalbu-
minuria than does office measurement.4,5
ABPM also has a better correlation with several
patient-oriented outcomes.  A cohort study of 1076
patients found that an elevation in ABPM was a bet-
ter predictor of cardiovascular events and overall
mortality than office measurements.6  Another cohort
study of 1464 patients found ABPM was linearly
related to stroke risk and more predictive of a cere-
brovascular event than was screening blood pres-
sure over an average of 6.4 years.7
In a randomized parallel-group trial, 419 untreat-
ed patients were followed up using either ABPM or
conventional office measurements to initiate and
adjust antihypertensive therapy.8 When compared
with standard office measurement, management
with ABPM led to less intensive antihypertensive
drug therapy without loss of blood pressure control.
Evidence from these and other studies indicates that
ABPM can be useful for risk stratification of patients
in whom the diagnosis of hypertension is not clear.9
However, trials studying the long-term outcomes of
the treatment of ambulatory blood pressure levels
are still lacking.
RECOMMENDATIONS FROM OTHERS
An ad hoc committee of the American Society of
Hypertension, the Canadian Hypertension Society,
and the British Hypertension Society all agree that
ABPM is useful in excluding the diagnosis of white-
coat hypertension and evaluating resistant hyper-
tension or episodic hypertension.1 The sixth report
of the Joint National Committee on Prevention,
Detection, Evaluation and Treatment of
Hypertension and the National High Blood Pressure
Education Program working group on ambulatory
blood pressure monitoring add that ABPM plays a
limited role in the routine evaluation of patients
with suspected hypertension.1
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CLINICAL COMMENTARY
Why has ABPM not supplanted office-based sphyn-
gomanometry as a preferred measurement tech-
nique? Because it is inconvenient. The first barrier to
eliminating hypertension is getting blood pressure
readings in the first place, and ABPM is not well
suited for this. But in borderline or difficult situa-
tions (eg, white-coat or nocturnal hypertension),
where multiple determinations are necessary, ABPM
has something to offer.  Perhaps its greatest value is
in developing more parsimonious and effective
treatment regimens for treatment-resistant patients,
or those for whom side effects are a problem.
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